EUVIMEDEUVIMED entdecken
Crossref

A Review of the Management of Chronic Myeloid Leukemia with Dasatinib

Joanna Gora-Tybor, Tadeusz Robak

Clinical Medicine. Therapeutics · 2009

DOI: 10.4137/cmt.s1167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Medicine. Therapeutics, 2009. Verfasst von Joanna Gora-Tybor und 1 weiteren Autor:innen. Die Arbeit nennt 65 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dasatinib is a multitargeted tyrosine kinase inhibitor (TKI), recommended for chronic myeloid leukemia (CML) in chronic, accelerated and blastic phases that are resistant or intolerant to imatinib. The recognition of BCR-ABL gene and corresponding protein with deregulated tyrosine kinase (TK) activity as crucial for malignant transformation in CML, led to synthesis of the small-molecule drugs designed to interfere with Bcr-Abl TK activation. The first TKI introduced into clinical practice in 1998, was imatinib mesylate, which became the first choice drug in chronic phase CML. However, approximately 20%-25% of patients initially successfully treated with imatinib, develop resistance to this drug, mainly because of selection of clones expressing mutant forms of BCR-ABL with impairing imatinib binding. Dasatinib is 325-fold more potent than imatinib against cell expressing wild-type BCR-ABL and showing activity against most imatinib-resistant Bcr-Abl mutants. Several clinical trials demonstrated that dasatinib is effective and generally well tolerated in imatinib resistant or intolerant CML and represents a promising therapeutic option for these patients.

Zitieren

APA

Gora-Tybor, J., & Robak, T. (2009). A Review of the Management of Chronic Myeloid Leukemia with Dasatinib. Clinical Medicine. Therapeutics. https://doi.org/10.4137/cmt.s1167

Vancouver

Gora-Tybor J, Robak T. A Review of the Management of Chronic Myeloid Leukemia with Dasatinib. Clinical Medicine. Therapeutics. 2009. doi:10.4137/cmt.s1167

BibTeX
@article{GoraTybor2009,
  author = {Gora-Tybor, Joanna and Robak, Tadeusz},
  title = {A Review of the Management of Chronic Myeloid Leukemia with Dasatinib},
  journal = {Clinical Medicine. Therapeutics},
  year = {2009},
  doi = {10.4137/cmt.s1167}
}
Kostenlos starten →